KR100797308B1 - 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법 - Google Patents

인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법 Download PDF

Info

Publication number
KR100797308B1
KR100797308B1 KR1020077020771A KR20077020771A KR100797308B1 KR 100797308 B1 KR100797308 B1 KR 100797308B1 KR 1020077020771 A KR1020077020771 A KR 1020077020771A KR 20077020771 A KR20077020771 A KR 20077020771A KR 100797308 B1 KR100797308 B1 KR 100797308B1
Authority
KR
South Korea
Prior art keywords
antibody
antibodies
erbb2
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077020771A
Other languages
English (en)
Korean (ko)
Other versions
KR20070094993A (ko
Inventor
카멜리아 더블유. 애덤스
레오나드 지. 프레스타
마크 슬리우코우스키
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22495168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100797308(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20070094993A publication Critical patent/KR20070094993A/ko
Application granted granted Critical
Publication of KR100797308B1 publication Critical patent/KR100797308B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
  • Medicinal Preparation (AREA)
KR1020077020771A 1999-06-25 2000-06-23 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법 Expired - Lifetime KR100797308B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14131699P 1999-06-25 1999-06-25
US60/141,316 1999-06-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020017016490A Division KR100850389B1 (ko) 1999-06-25 2000-06-23 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법

Publications (2)

Publication Number Publication Date
KR20070094993A KR20070094993A (ko) 2007-09-27
KR100797308B1 true KR100797308B1 (ko) 2008-01-23

Family

ID=22495168

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077020771A Expired - Lifetime KR100797308B1 (ko) 1999-06-25 2000-06-23 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
KR1020017016490A Expired - Lifetime KR100850389B1 (ko) 1999-06-25 2000-06-23 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020017016490A Expired - Lifetime KR100850389B1 (ko) 1999-06-25 2000-06-23 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법

Country Status (32)

Country Link
EP (2) EP2112167A3 (enExample)
JP (2) JP4283474B2 (enExample)
KR (2) KR100797308B1 (enExample)
CN (4) CN100340575C (enExample)
AR (1) AR024464A1 (enExample)
AT (2) ATE437655T1 (enExample)
AU (2) AU784045B2 (enExample)
BE (1) BE2013C020I2 (enExample)
BR (2) BR122014028365B8 (enExample)
CA (2) CA2727172A1 (enExample)
CH (1) CH694589A5 (enExample)
CY (2) CY1109525T1 (enExample)
CZ (1) CZ299702B6 (enExample)
DE (2) DE10084743T1 (enExample)
DK (1) DK1189641T5 (enExample)
ES (1) ES2329437T3 (enExample)
FR (1) FR13C0016I2 (enExample)
GB (1) GB2368796B (enExample)
GE (1) GEP20104998B (enExample)
HU (1) HU226742B1 (enExample)
IL (3) IL146954A0 (enExample)
LU (1) LU92164I2 (enExample)
MX (1) MXPA01013458A (enExample)
NO (3) NO328377B1 (enExample)
NZ (2) NZ531426A (enExample)
PL (2) PL203326B1 (enExample)
PT (1) PT1189641E (enExample)
RU (2) RU2270029C2 (enExample)
SI (3) SI1189641T1 (enExample)
TR (1) TR200103756T2 (enExample)
WO (1) WO2001000245A2 (enExample)
ZA (2) ZA200109786B (enExample)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
GEP20104998B (en) * 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2977063A1 (en) * 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
EP2111870A1 (en) 1999-08-27 2009-10-28 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
EP1228766A1 (en) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
CH696871A5 (de) * 2001-10-26 2008-01-15 Altarex Medical Corp Verwendung eines chemotherapeutischen Arzneimittels und einer Zusammensetzung, die ein Bindemittel umfasst, zur Herstellung eines Medikamentes zur Krankheitsbehandlung.
MXPA04009809A (es) * 2002-04-11 2004-12-13 Amgen Inc Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas.
ITTO20020340A1 (it) * 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
US7198899B2 (en) 2002-06-03 2007-04-03 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NO340576B1 (no) * 2002-07-11 2017-05-15 Hoffmann La Roche Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
EP2263691B1 (en) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US7211250B2 (en) * 2002-07-18 2007-05-01 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
KR101115797B1 (ko) * 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP1572131B1 (en) * 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CA2518716A1 (en) * 2003-03-11 2005-01-13 Dana-Farber Cancer Institute Inhibition of viral pathogenesis
MXPA05011406A (es) * 2003-04-23 2005-12-12 Medarex Inc Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
PL3095793T3 (pl) 2003-07-28 2020-09-07 Genentech, Inc. Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
WO2005020923A2 (en) * 2003-08-29 2005-03-10 Cedars-Sinai Medical Center Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
BRPI0414513A (pt) * 2003-09-18 2007-01-02 Raven Biotechnologies Inc kid3 e anticorpos de kid3 que se ligam a ele
MXPA06006009A (es) * 2003-11-28 2006-09-04 Mitra Medical Technology Ab Direccionamiento de antigenos erb.
RU2402568C2 (ru) * 2004-02-06 2010-10-27 МорфоСис АГ Человеческие анти-cd38-антитела и их применение
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
MXPA06014065A (es) * 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
AU2005287404B2 (en) 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
MX2007008768A (es) 2005-01-21 2007-10-19 Genentech Inc Dosificacion fija de anticuerpos her.
CN103251946A (zh) 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
KR101164820B1 (ko) 2005-09-22 2012-07-12 삼성전자주식회사 디스플레이장치
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
KR20090019890A (ko) * 2006-06-05 2009-02-25 제넨테크, 인크. Ｅｇｆ 또는 ｔｇｆ-알파 수준이 상승된 암 환자의 생존 연장
MY150756A (en) 2006-08-21 2014-02-28 Hoffmann La Roche Tumor theraphy with an anti-vegf antibody
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
CN101594883B (zh) * 2006-10-12 2018-04-10 中外制药株式会社 使用抗ereg抗体的癌症的诊断和治疗
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
PE20090681A1 (es) * 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
JP2010530437A (ja) * 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CL2008003218A1 (es) 2007-10-30 2009-03-06 Genentech Inc Método para la purificación de un anticuerpo a partir de una composición que comprende el anticuerpo y al menos un contaminante.
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
AU2008340053A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as PI 3 kinase inhibitors
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
US9879267B2 (en) 2008-03-14 2018-01-30 Genentech, Inc. Genetic variations associated with drug resistance
HUE025507T2 (en) * 2008-03-18 2016-02-29 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010030670A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
HRP20230487T1 (hr) 2009-02-13 2023-07-21 Immunomedics, Inc. Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti
CN102356092B (zh) 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
MX2011010158A (es) 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
TW201431558A (zh) * 2009-08-15 2014-08-16 建南德克公司 用於治療先前治療過之乳癌之抗-血管新生療法
CA2772653C (en) 2009-09-01 2019-06-25 Genentech, Inc. Enhanced protein purification through a modified protein a elution
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR101808602B1 (ko) 2009-10-07 2017-12-13 마크로제닉스, 인크. 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
ES2639056T3 (es) * 2009-10-28 2017-10-25 Abbvie Biotherapeutics Inc. Anticuerpos anti-EGFR y sus usos
TWI600760B (zh) 2009-11-05 2017-10-01 建南德克公司 分泌異源多肽之方法及組合物
NO2719708T3 (enExample) 2009-11-13 2018-03-24
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
MX340014B (es) * 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
KR102218495B1 (ko) 2010-03-22 2021-02-19 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
RU2614125C2 (ru) 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
JP2013534520A (ja) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
MY161390A (en) 2010-06-24 2017-04-14 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
MX357821B (es) 2010-12-21 2018-07-25 Hoffmann La Roche Preparación de anticuerpo enriquecida con isoforma y método para obtenerla.
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP6162044B2 (ja) 2010-12-23 2017-07-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 結合剤
TW201309700A (zh) 2011-01-31 2013-03-01 Novartis Ag 新穎雜環衍生物
CN103649326B (zh) * 2011-03-08 2016-08-17 宾夕法尼亚大学理事会 用于治疗和诊断用途的抗体样蛋白
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
DK4403228T3 (da) 2011-10-14 2025-10-13 Hoffmann La Roche Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013061305A1 (en) 2011-10-28 2013-05-02 Novartis Ag Novel purine derivatives and their use in the treatment of disease
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
IL267585B (en) 2011-12-22 2022-09-01 Genentech Inc Ion exchange membrane chromatography
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
AU2013214254B2 (en) 2012-01-31 2016-04-21 Novartis Ag Method of treating cancer
EP2638916A1 (en) 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
EP2849756A1 (en) 2012-05-16 2015-03-25 Novartis AG Dosage regimen for a pi-3 kinase inhibitor
BR112015012644A2 (pt) 2012-11-30 2017-12-19 Hoffmann La Roche método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
ES2651331T3 (es) 2013-01-10 2018-01-25 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibidores de la sintasa de ácidos grasos
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CN104628846B (zh) 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
JP6326137B2 (ja) 2013-11-19 2018-05-16 烟台▲榮▼昌生物工程有限公司Ｒｅｍｅｇｅｎ， Ｌｔｄ． 抗ｈｅｒ２抗体及びその結合体
MX376384B (es) 2013-11-27 2025-03-07 Zymeworks Bc Inc Construcciones de union a antigenos biespecificas dirigidas a her2.
CA2930359C (en) 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
CA2928794C (en) 2014-01-31 2019-08-13 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
US20160361309A1 (en) 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
WO2015139046A1 (en) 2014-03-14 2015-09-17 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
EP3129055B1 (en) 2014-04-11 2020-07-01 MedImmune, LLC Bispecific her2 antibodies
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
IL251210B2 (en) 2014-09-19 2023-12-01 Siwa Corp Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
CA2968258A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3294772B1 (en) * 2015-05-13 2025-11-05 Zymeworks BC Inc. Antigen-binding constructs targeting her2
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
EP3362483A1 (en) * 2015-10-13 2018-08-22 Siwa Corporation Anti-age antibodies and methods of use thereof
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
CN105646704B (zh) * 2015-12-28 2019-11-15 广西医科大学 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
AU2017235450A1 (en) * 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
US11142585B2 (en) * 2016-05-12 2021-10-12 Agency For Science, Technology And Research Anti-ERBB-2 antibodies and uses thereof
EP3475306A1 (en) 2016-06-23 2019-05-01 Siwa Corporation Vaccines for use in treating various diseases and disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018066626A1 (ja) 2016-10-07 2018-04-12 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP7069476B2 (ja) * 2017-01-06 2022-05-18 博奥信生物技▲術▼（南京）有限公司 ＥｒｂＢ２抗体およびその使用
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
AR111249A1 (es) 2017-03-22 2019-06-19 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
WO2019039483A1 (ja) 2017-08-23 2019-02-28 第一三共株式会社 抗体－薬物コンジュゲートの製剤及びその凍結乾燥方法
WO2019044946A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
AU2019222666B2 (en) 2018-02-15 2025-12-04 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
EP3560945A1 (en) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
JP7441165B2 (ja) 2018-05-28 2024-02-29 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
TWI865337B (zh) 2018-07-25 2024-12-01 日商第一三共股份有限公司 抗體-藥物結合物之有效的製造方法
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
CA3108754A1 (en) 2018-08-06 2020-02-13 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
JP7481255B2 (ja) 2018-08-23 2024-05-10 第一三共株式会社 抗体薬物複合体の感受性マーカー
CA3114395A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
JP7608164B2 (ja) 2018-12-11 2025-01-06 第一三共株式会社 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
MX2021007260A (es) 2018-12-19 2021-09-08 Incyte Corp Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CA3128064A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
CN112007169B (zh) * 2019-05-30 2022-03-08 湖南大学 一种核酸适配体药物偶联物及其制备方法和用途
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
BR112021025476A2 (pt) 2019-06-26 2022-10-11 Glaxosmithkline Ip Dev Ltd Proteínas de ligação à il1rap
CN110551214A (zh) * 2019-08-27 2019-12-10 杨澜 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
EP4096718A1 (en) 2020-01-28 2022-12-07 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4106813A4 (en) 2020-02-21 2024-03-27 MacroGenics, Inc. CD137 BINDING MOLECULES AND THEIR USES
WO2021260579A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
CN116615248A (zh) 2020-06-24 2023-08-18 阿斯利康(英国)有限公司 抗体-药物缀合物和cdk9抑制剂的组合
CA3186675A1 (en) 2020-07-20 2022-01-27 Yasuki KAMAI Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
WO2022074617A1 (en) 2020-10-09 2022-04-14 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
US20230414778A1 (en) 2020-11-11 2023-12-28 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
US20250161305A1 (en) 2021-12-28 2025-05-22 Astrazeneca Uk Limited Combination of antibody-drug conjugate and rasg12c inhibitor
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
JP2025517656A (ja) 2022-05-11 2025-06-10 第一三共株式会社 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
JP2025524992A (ja) 2022-07-28 2025-08-01 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートと二重特異性チェックポイント阻害剤との組み合わせ
WO2025088496A1 (en) 2023-10-24 2025-05-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and anti-pd-1/tim-3 bispecific binding protein
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途
WO2025120513A1 (en) 2023-12-05 2025-06-12 Astrazeneca Uk Limited Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1998017797A1 (en) * 1996-10-18 1998-04-30 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0491675A1 (en) 1984-01-30 1992-06-24 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1994000136A1 (en) 1992-06-30 1994-01-06 Oncologix, Inc. A COMBINATION OF ANTI-erbB-2 MONOCLONAL ANTIBODIES AND METHOD OF USING
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
EP0616812B1 (en) 1993-03-24 1999-11-03 Berlex Biosciences Combination with anti-hormonal compounds and binding molecules for the treatment of cancer
WO1994022478A1 (en) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
WO1995014776A1 (en) 1993-11-23 1995-06-01 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP1241264A1 (en) 1994-12-02 2002-09-18 Chiron Corporation Monoclonal antibodies to colon cancer antigen
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
IL127892A0 (en) * 1996-07-12 1999-10-28 Genentech Inc Gamma-heregulin
AU729247B2 (en) * 1996-08-12 2001-01-25 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1187632B1 (en) * 1999-05-14 2008-12-03 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
CA2383493C (en) * 1999-06-25 2010-08-10 Genentech, Inc. Treating prostate cancer with anti-erbb2 antibodies
GEP20104998B (en) * 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
EP2977063A1 (en) * 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP2111870A1 (en) * 1999-08-27 2009-10-28 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
WO1998017797A1 (en) * 1996-10-18 1998-04-30 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Also Published As

Publication number Publication date
DE60042648D1 (de) 2009-09-10
CN101121750A (zh) 2008-02-13
AR024464A1 (es) 2002-10-02
ES2329437T3 (es) 2009-11-26
AU2005242195B2 (en) 2009-06-11
NZ531426A (en) 2005-10-28
HUP0201695A2 (en) 2002-09-28
GB0200506D0 (en) 2002-02-27
EP2112167A2 (en) 2009-10-28
AT500848A1 (de) 2006-04-15
IL146954A (en) 2009-09-22
CY2013010I2 (el) 2015-08-05
GB2368796B (en) 2004-08-04
HU226742B1 (en) 2009-08-28
CA2727172A1 (en) 2001-01-04
CN101518653B (zh) 2015-08-19
RU2430739C2 (ru) 2011-10-10
RU2270029C2 (ru) 2006-02-20
CN101518653A (zh) 2009-09-02
BR0012198A (pt) 2002-04-02
BE2013C020I2 (enExample) 2019-08-21
EP2112167A3 (en) 2010-12-22
LU92164I2 (fr) 2013-05-07
PT1189641E (pt) 2009-11-04
JP2009142280A (ja) 2009-07-02
CA2376596C (en) 2009-10-06
CA2376596A1 (en) 2001-01-04
MXPA01013458A (es) 2002-07-30
DK1189641T5 (da) 2011-04-11
HUP0201695A3 (en) 2005-06-28
FR13C0016I2 (fr) 2014-05-16
ZA200110263B (en) 2003-02-26
RU2430739C9 (ru) 2015-12-20
EP1189641A2 (en) 2002-03-27
NO2013005I1 (no) 2013-04-02
AT500848B1 (de) 2008-01-15
NO336040B1 (no) 2015-04-27
TR200103756T2 (tr) 2002-06-21
ATE437655T1 (de) 2009-08-15
KR20020068264A (ko) 2002-08-27
CY1109525T1 (el) 2014-08-13
PL204629B1 (pl) 2010-01-29
RU2005132788A (ru) 2007-04-27
NO2013005I2 (no) 2013-03-12
WO2001000245A3 (en) 2001-10-25
NO20016329D0 (no) 2001-12-21
AU2005242195A1 (en) 2006-01-12
SI1189641T1 (sl) 2009-12-31
KR20070094993A (ko) 2007-09-27
DK1189641T3 (da) 2009-11-16
CZ20014596A3 (cs) 2003-02-12
AU784045B2 (en) 2006-01-19
EP1189641B1 (en) 2009-07-29
ZA200109786B (en) 2002-11-28
JP4283474B2 (ja) 2009-06-24
BR122014028365B1 (pt) 2020-01-28
WO2001000245A2 (en) 2001-01-04
CH694589A5 (de) 2005-04-15
NO20091792L (no) 2002-02-25
PL352321A1 (en) 2003-08-11
DE10084743T1 (de) 2002-08-14
HK1044888A1 (en) 2002-11-08
CZ299702B6 (cs) 2008-10-22
CN101121021A (zh) 2008-02-13
CN1370082A (zh) 2002-09-18
CY2013010I1 (el) 2015-08-05
NZ516830A (en) 2004-07-30
PL203326B1 (pl) 2009-09-30
BR122014028365B8 (pt) 2021-07-06
CN100340575C (zh) 2007-10-03
GB2368796A (en) 2002-05-15
AU5763200A (en) 2001-01-31
SI2283866T1 (sl) 2015-07-31
CN101121021B (zh) 2011-12-07
IL197359A0 (en) 2011-07-31
JP2003503366A (ja) 2003-01-28
GEP20104998B (en) 2010-06-10
BRPI0012198B8 (pt) 2021-05-25
FR13C0016I1 (enExample) 2013-04-12
BRPI0012198B1 (pt) 2016-12-20
SI2283867T1 (sl) 2014-07-31
NO20016329L (no) 2002-02-25
NO328377B1 (no) 2010-02-08
IL146954A0 (en) 2002-08-14
KR100850389B1 (ko) 2008-08-04

Similar Documents

Publication Publication Date Title
KR100797308B1 (ko) 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
US7618631B2 (en) Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
KR100754049B1 (ko) 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물
US20070184055A1 (en) Treatment with anti-erbb2 antibodies
US20040013667A1 (en) Treatment with anti-ErbB2 antibodies
HK1044888B (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
HK1130502A (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070911

Application number text: 1020017016490

Filing date: 20011222

PA0201 Request for examination
PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20071210

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080116

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080116

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20101222

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20111223

Start annual number: 5

End annual number: 5

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20121119

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20080116

Patent event code: PJ02021E01I

Appeal kind category: Correction

Decision date: 20130614

Request date: 20121119

Appeal identifier: 2012105000129

PR1001 Payment of annual fee

Payment date: 20121227

Start annual number: 6

End annual number: 6

PG1701 Publication of correction

Publication date: 20130412

J301 Trial decision

Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20121119

Effective date: 20130614

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20130614

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20121119

Decision date: 20130614

Appeal identifier: 2012105000129

PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20130829

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20131227

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20131227

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20141230

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20141230

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20151230

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20161229

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20171228

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20191227

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20200625

Start annual number: 14

End annual number: 17

PC1801 Expiration of term

Termination date: 20241106

Termination category: Expiration of duration